News und Analysen
Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed
Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed
Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split
Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split
Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis
Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis
Publication of unaudited financial statements of Kinarus Therapeutics Holding AG (only) for FY2023
Publication of unaudited financial statements of Kinarus Therapeutics Holding AG (only) for FY2023
Courts of Basel-Stadt have revoked bankruptcy of Kinarus Therapeutics Holding AG
Courts of Basel-Stadt have revoked bankruptcy of Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG in Liquidation and Curatis AG propose to combine companies and reverse bankruptcy procedures of Kinarus Therapeutics Holding AG in Liquidation
Kinarus Therapeutics Holding AG in Liquidation and Curatis AG propose to combine companies and reverse bankruptcy procedures of Kinarus Therapeutics Holding AG in Liquidation
Kinarus Therapeutics has decided to file for bankruptcy
Kinarus Therapeutics has decided to file for bankruptcy
Kinarus Therapeutics Group Reports First Half 2023 Financial Results
Kinarus Therapeutics Group Reports First Half 2023 Financial Results
Kinarus Therapeutics signed licensing agreement to extend cash for operations
Kinarus Therapeutics signed licensing agreement to extend cash for operations
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
Kinarus Therapeutics Group Reports 2022 Annual Results
Kinarus Therapeutics Group Reports 2022 Annual Results
Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management
Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management
Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures
Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures
Kinarus Therapeutics Holding AG ('Kinarus') receives deadline extension from SER for publication of its 2022 annual financial report
Kinarus Therapeutics Holding AG ('Kinarus') receives deadline extension from SER for publication of its 2022 annual financial report
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update